Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.57 |
| ▸ | PRCP | P42785 | 5/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330238 | 1.00 | OPRM1 (0.57) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL329828 | 1.00 | OPRM1 (0.57) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL3453173 | 0.98 | OPRM1 (0.56) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL329886 | 0.85 | OPRM1 (0.59) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL8790382 | 0.84 | OPRM1 (0.49) | OPRM1PRCPSLC22A1SMN1; SMN2KDM4E | |
| SCHEMBL9530399 | 0.84 | OPRM1 (0.54) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9423819 | 0.83 | PRCP (0.56) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9373834 | 0.81 | PRCP (0.51) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9373842 | 0.81 | PRCP (0.51) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9373828 | 0.81 | PRCP (0.51) | OPRM1PRCPSLC22A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | claimed |
| WO-1996005817-A1 | MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF INCONTINENCE | MEDINNOVA SF (NO) | 1996-02-29 | — | — | WO | claimed |
| US-5096908-A | 5-HT1A agonist | ELI LILLY AND COMPANY (US) | 1992-03-17 | — | — | US | claimed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | claimed |
| JP-4270219-A | — | — | None | — | — | JP | disclosed |
| CN-103145715-B | Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors | F·霍夫曼-罗须公司 | 2016-08-03 | — | — | CN | disclosed |
| EP-1680137-B1 | Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication | HOFFMANN LA ROCHE (CH) | 2012-11-21 | — | — | EP | disclosed |
| EP-2407470-A2 | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | F. Hoffmann-La Roche Ltd. (CH) | 2012-01-18 | — | — | EP | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-5340838-A | Administering serotonin agonist to mammals | ELI LILLY AND COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| US-5258379-A | ADMINISTERING IN AN EFFECTIVE DOSAGE TO MAMMALS | ELI LILLY AND COMPANY (US) | 1993-11-02 | — | — | US | disclosed |
| US-5158956-A | Administering serotonin receptor agonist | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| JP-H04270219-A | GASTRIC ACID SECRETION INHIBITOR | ELI LILLY & CO | 1992-09-25 | — | — | JP | disclosed |
| US-5096908-A | 5-HT1A agonist | ELI LILLY AND COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| US-5041451-A | Analgesics, hypotensive agents | DR. LO. ZAMBELLETTI SPA (IT) | 1991-08-20 | — | — | US | disclosed |
| EP-0370732-A2 | Heterocyclic compounds containing nitrogen | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | OPRM1 3264/4885PRCP 974/4885SLC22A1 3482/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | OPRM1 3264/4885PRCP 974/4885SLC22A1 3482/4885 |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | OPRM1 3264/4885PRCP 974/4885SLC22A1 3482/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | OPRM1 3264/4885PRCP 974/4885SLC22A1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.